AstraZeneca Gross Profit 2006-2018 | AZN

AstraZeneca annual/quarterly gross profit history and growth rate from 2006 to 2018. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • AstraZeneca gross profit for the quarter ending December 31, 2018 was $4.780B, a 5.01% increase year-over-year.
  • AstraZeneca gross profit for the twelve months ending December 31, 2018 was $17.154B, a 5.47% decline year-over-year.
  • AstraZeneca annual gross profit for 2018 was $17.154B, a 5.47% decline from 2017.
  • AstraZeneca annual gross profit for 2017 was $18.147B, a 3.86% decline from 2016.
  • AstraZeneca annual gross profit for 2016 was $18.876B, a 5.91% decline from 2015.
AstraZeneca Annual Gross Profit
(Millions of US $)
2018 $17,154
2017 $18,147
2016 $18,876
2015 $20,062
2014 $20,705
2013 $20,545
2012 $22,580
2011 $27,565
2010 $26,880
2009 $27,029
2008 $25,003
2007 $23,140
2006 $20,916
2005 $18,594
AstraZeneca Quarterly Gross Profit
(Millions of US $)
Q4 2018 $4,780
Q3 2018 $4,187
Q2 2018 $4,143
Q1 2018 $4,044
Q4 2017 $4,552
Q3 2017 $4,983
Q2 2017 $4,101
Q1 2017 $4,511
Q4 2016 $4,425
Q3 2016 $4,799
Q2 2016 $4,541
Q1 2016 $5,111
Q4 2015 $5,130
Q3 2015 $4,904
Q2 2015 $5,240
Q1 2015 $4,788
Q4 2014 $5,049
Q3 2014 $5,194
Q2 2014 $5,455
Q1 2014 $5,007
Q4 2013 $5,499
Q3 2013 $5,012
Q2 2013 $4,915
Q1 2013 $5,119
Q4 2012 $5,884
Q3 2012 $5,408
Q2 2012 $5,314
Q1 2012 $5,974
Q4 2011 $7,044
Q3 2011 $6,620
Q2 2011 $6,948
Q1 2011 $6,953
Q4 2010 $6,858
Q3 2010 $6,374
Q2 2010 $6,726
Q1 2010 $6,922
Q4 2009 $7,280
Q3 2009 $6,937
Q2 2009 $6,494
Q1 2009 $6,318
Q4 2008 $6,081
Q3 2008 $6,246
Q2 2008 $6,501
Q1 2008 $6,175
Q4 2007 $8,170
Q3 2007 $7,150
Q2 2007 $5,632
Q1 2007 $5,480
Q4 2006 $5,576
Q3 2006 $5,177
Q2 2006 $5,234
Q1 2006 $4,929
Q4 2005 $4,948
Q3 2005 $4,544
Q2 2005 $4,817
Q1 2005 $4,283
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.200B $22.090B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $371.636B 16.85
Pfizer (PFE) United States $237.400B 13.29
Merck (MRK) United States $199.302B 17.03
Novartis AG (NVS) Switzerland $178.563B 15.19
Eli Lilly (LLY) United States $120.673B 20.95
Novo Nordisk (NVO) Denmark $118.536B 19.17
AbbVie (ABBV) United States $115.027B 9.86
Sanofi (SNY) France $103.057B 12.72
GlaxoSmithKline (GSK) United Kingdom $99.174B 13.02
Bristol-Myers Squibb (BMY) United States $74.835B 11.51